Predictive Value of Neutrophil Subtypes in Response to Neoadjuvant Therapy in Breast Cancer Patients.

Linxiaoxi Ma,Liang Guo,Zhimin Shao,Xiaoming Zhang,Jiong Wu

DOI: https://doi.org/10.1200/jco.2018.36.15_suppl.e12642

IF: 45.3

2018-01-01

Journal of Clinical Oncology

Abstract:e12642 Background: Several studies reported on effective predictive markers of neoadjuvant therapies in breast cancer. However, the predictive value of polymorphonuclear neutrophil (PMN) subtypes remains unclear so far. Methods: Blood samples of 180 breast cancer patients before treated with neoadjuvant therapy and 118 healthy donators from Fudan University Shanghai Cancer Center were collected in this prospective study during July 2015 to October 2016. PMN subtypes were analyzed with multiparameter flow cytometry. Neoadjuvant therapeutic regimen mainly included taxanes with sequential anthracyclines. In Her-2 positive diseases, paclitaxel-carboplatin-trastuzumab regimen was the main choice. In this series of patients, at least 4-6 cycles would be delivered pre-operatively. Pathologic evaluation after surgery showed 35 pathologic complete response (PCR) and 145 non-PCR. The association in PMN subtypes is examined with t test, and others with Χ2 test. Results: PMN was divided into 4 subtypes based on CD16 and CD62L: CD16-CD62L-(Early), CD16-CD62L+(Immature), CD16+CD62L+(Mature), and CD16+CD62L-(Activated). In addition, HLADR+ PMN was defined as “DR+ PMN”. Compared with healthy donators, breast cancer patients had lower CD16+CD62L+ PMN (P < 0.001), higher CD16+CD62L- PMN (P = 0.001) and DR+PMN (P < 0.001). We further investigated patients treated with neoadjuvant therapy and found that PCR patients had higher CD16+CD62L+PMN (P = 0.019). Univariable regression analysis demonstrates markers associated with PCR were ER negative (O.R. = 2.125, 95% CI 1.308-3.452, P = 0.002), Her-2 positive (O.R. = 2.217, 95% CI 1.355-3.628, P = 0.002), CD16+CD62L+ PMN(%) > 97.4 (O.R. = 3.276, 95% CI 2.161-4.965, P < 0.001). Multivariate regression analysis indicates CD16+CD62L+ PMN(%) > 97.4 (O.R. = 6.493, 95% CI 368-12.521, P < 0.001) was the independent predictors of PCR. Conclusions: PMN status was different between healthy people and breast cancer patients. It was indicated that peripheral blood PMN subtype could have predictive value after neoadjuvant systemic treatment in breast cancer patients. Further validation study should be warranted to test its significance in clinical practice.